{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:06:06Z","timestamp":1791644766925,"version":"4.3.4"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.phrs.2025.107985","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T04:47:56Z","timestamp":1760071676000},"page":"107985","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Drugs for transthyretin amyloidosis under the microscope: Survival, safety, and a meta-analysis with certainty of evidence assessment"],"prefix":"10.1016","volume":"221","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6558-3065","authenticated-orcid":false,"given":"Eugenia","family":"Piragine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5608-5902","authenticated-orcid":false,"given":"Ersilia","family":"Lucenteforte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Veneziano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1441-5421","authenticated-orcid":false,"given":"Vincenzo","family":"Calderone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2090-7107","authenticated-orcid":false,"given":"Alma","family":"Martelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2025.107985_bib1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13023-025-03547-0","article-title":"Epidemiology of transthyretin (ATTR) amyloidosis: a systematic literature review","volume":"20","author":"Delgado","year":"2025","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.phrs.2025.107985_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107344","article-title":"Anti-amyloid immunotherapy in alzheimer's disease: the new Dawn emerging from 179 clinical trials","volume":"208","author":"Fan","year":"2024","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2025.107985_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106631","article-title":"Role of monomeric amyloid-\u03b2 in cognitive performance in alzheimer's disease: insights from clinical trials with secretase inhibitors and monoclonal antibodies","volume":"187","author":"Imbimbo","year":"2023","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2025.107985_bib4","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jaccao.2021.09.003","article-title":"AL amyloidosis: current chemotherapy and immune therapy treatment strategies","volume":"3","author":"Bianchi","year":"2021","journal-title":"JACC CardioOncology StateArt. Rev. JACC CardioOncol"},{"key":"10.1016\/j.phrs.2025.107985_bib5","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s40120-020-00217-0","article-title":"A narrative review of the role of transthyretin in health and disease","volume":"9","author":"Liz","year":"2020","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.phrs.2025.107985_bib6","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of Wild-Type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2025.107985_bib7","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2025.107985_bib8","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1001\/jama.2024.0442","article-title":"Cardiac amyloidosis due to transthyretin protein: a review","volume":"331","author":"Ruberg","year":"2024","journal-title":"Jama"},{"key":"10.1016\/j.phrs.2025.107985_bib9","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000006543","article-title":"Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy","volume":"91","author":"Coelho","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.phrs.2025.107985_bib10","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40120-020-00183-7","article-title":"Impact of Non-Cardiac clinicopathologic characteristics on survival in transthyretin amyloid polyneuropathy","volume":"9","author":"Gonz\u00e1lez-Duarte","year":"2020","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.phrs.2025.107985_bib11","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1016\/j.jacc.2015.09.075","article-title":"Diagnosis, prognosis, and therapy of transthyretin amyloidosis","volume":"66","author":"Gertz","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2025.107985_bib12","first-page":"93","article-title":"Evolving strategies in cardiac amyloidosis: from mechanistic discoveries to diagnostic and therapeutic advances","volume":"43","author":"Stein-Merlob","year":"2025","journal-title":"Cardiol. Clin."},{"key":"10.1016\/j.phrs.2025.107985_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107102","article-title":"Nanoparticles and siRNA: a new era in therapeutics?","volume":"201","author":"P\u00e9rez-Carri\u00f3n","year":"2024","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2025.107985_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107083","article-title":"Metabolic disorders affecting the liver and heart: therapeutic efficacy of miRNA-based therapies?","volume":"201","author":"La Sala","year":"2024","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2025.107985_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107487","article-title":"Global and Chinese trends in oligonucleotide drug clinical development: a comparative analysis","volume":"210","author":"Wu","year":"2024","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2025.107985_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107279","article-title":"The function and therapeutic potential of transfer RNA-derived small RNAs in cardiovascular diseases: a review","volume":"206","author":"Wang","year":"2024","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2025.107985_bib17","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s40259-023-00577-7","article-title":"RNA targeting and gene editing strategies for transthyretin amyloidosis","volume":"37","author":"Ioannou","year":"2023","journal-title":"BioDrugs"},{"key":"10.1016\/j.phrs.2025.107985_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102172","article-title":"Tafamidis treatment in patients with transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis","volume":"63","author":"Wang","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.phrs.2025.107985_bib19","article-title":"A systematic review of tafamidis in patients with transthyretin amyloid cardiomyopathy","volume":"13","author":"Singh","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.phrs.2025.107985_bib20","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1186\/s12872-025-04653-4","article-title":"The efficacy and safety of specific therapies for cardiac Transthyretin-mediated amyloidosis: a systematic review and meta-analysis of randomized trials","volume":"25","author":"Prata","year":"2025","journal-title":"BMC Cardiovasc Disord."},{"key":"10.1016\/j.phrs.2025.107985_bib21","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst. Rev."},{"key":"10.1016\/j.phrs.2025.107985_bib22","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial","volume":"310","author":"Berk","year":"2013","journal-title":"Jama"},{"key":"10.1016\/j.phrs.2025.107985_bib23","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Bmj"},{"key":"10.1016\/j.phrs.2025.107985_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106519","article-title":"Potential effects of alliaceae and brassicaceae edible plants on blood glucose levels in patients with type 2 diabetes: a systematic review and meta-analysis of clinical trials","volume":"185","author":"Piragine","year":"2022","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2025.107985_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107251","article-title":"The association between endocrine disrupting chemicals and nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"205","author":"Pan","year":"2024","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2025.107985_bib26","unstructured":"J.M. Gierisch, C. Beadles, A. Shapiro, et al., Health Disparities in Quality Indicators of Healthcare Among Adults with Mental Illness [Internet]. Washington (DC): Department of Veterans Affairs (US); 2014 Oct. APPENDIX B, NEWCASTLE-OTTAWA SCALE CODING MANUAL FOR COHORT STUDIES. Available from: \u3008https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK299087\/\u3009."},{"key":"10.1016\/j.phrs.2025.107985_bib27","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med Res Method."},{"key":"10.1016\/j.phrs.2025.107985_bib28","unstructured":"J.P.T. Higgins, J. Thomas, J. Chandler, M. Cumpston, T. Li, M.J. Page, V.A. Welch (editors), Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane, 2024. Available from \u3008www.cochrane.org\/handbook\u3009."},{"key":"10.1016\/j.phrs.2025.107985_bib29","doi-asserted-by":"crossref","first-page":"5765","DOI":"10.1002\/ptr.8350","article-title":"Alliaceae versus brassicaceae for dyslipidemia: state of the art and future perspectives. Systematic review and Meta-Analysis of clinical studies","volume":"38","author":"Piragine","year":"2024","journal-title":"Phytother. Res"},{"key":"10.1016\/j.phrs.2025.107985_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106919","article-title":"Guideline on treating community-acquired pneumonia with Chinese patent medicines","volume":"196","author":"Wang","year":"2023","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2025.107985_bib31","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jclinepi.2020.09.018","article-title":"GRADE guidelines 30: the GRADE approach to assessing the certainty of modeled evidence-An overview in the context of health decision-making","volume":"129","author":"Brozek","year":"2021","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.phrs.2025.107985_bib32","unstructured":"The GRADE Book version 1.0 (updated September 2024). The GRADE Working Group. Available from: \u3008https:\/\/book.gradepro.org\u3009."},{"key":"10.1016\/j.phrs.2025.107985_bib33","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","article-title":"IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Med Res Method."},{"key":"10.1016\/j.phrs.2025.107985_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13216393","article-title":"Efficacy and safety of cardioband in patients with tricuspid regurgitation: systematic review and Meta-Analysis of Single-Arm trials and observational studies","volume":"13","author":"Piragine","year":"2024","journal-title":"J. Clin. Med"},{"key":"10.1016\/j.phrs.2025.107985_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/mps8010013","article-title":"The reconstructed individual patient data from Kaplan-Meier (IPDfromKM) method for Non-Inferiority analyses: a new potential application","volume":"8","author":"Piragine","year":"2025","journal-title":"Methods Protoc."},{"key":"10.1016\/j.phrs.2025.107985_bib36","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2025.107985_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial","volume":"30","author":"Adams","year":"2023","journal-title":"Amyloid"},{"key":"10.1016\/j.phrs.2025.107985_bib38","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2025.107985_bib39","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial","volume":"79","author":"Coelho","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.phrs.2025.107985_bib40","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1001\/jama.2023.18688","article-title":"Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy","volume":"330","author":"Coelho","year":"2023","journal-title":"Jama"},{"key":"10.1016\/j.phrs.2025.107985_bib41","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2025.107985_bib42","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2025.107985_bib43","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jacc.2019.03.012","article-title":"Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy","volume":"74","author":"Judge","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2025.107985_bib44","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2025.107985_bib45","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","article-title":"Patisiran treatment in patients with transthyretin cardiac amyloidosis","volume":"389","author":"Maurer","year":"2023","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2025.107985_bib46","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1001\/jamacardio.2019.0849","article-title":"Association of patisiran, an RNA interference therapeutic, with regional left ventricular myocardial strain in hereditary transthyretin amyloidosis: the APOLLO study","volume":"4","author":"Minamisawa","year":"2019","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.phrs.2025.107985_bib47","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/13506129.2020.1730790","article-title":"Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis","volume":"27","author":"Obici","year":"2020","journal-title":"Amyloid"},{"key":"10.1016\/j.phrs.2025.107985_bib48","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/13506129.2022.2118043","article-title":"Impact of baseline polyneuropathy severity on patisiran treatment outcomes in the APOLLO trial","volume":"30","author":"Quan","year":"2023","journal-title":"Amyloid"},{"key":"10.1016\/j.phrs.2025.107985_bib49","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/ejhf.2783","article-title":"Effect of patisiran on stroke volume in hereditary transthyretin-mediated amyloidosis: insights from pressure-volume analysis of the APOLLO study","volume":"25","author":"Rosenblum","year":"2023","journal-title":"Eur. J. Heart Fail"},{"key":"10.1016\/j.phrs.2025.107985_bib50","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary Transthyretin-Mediated amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2025.107985_bib51","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12883-023-03116-7","article-title":"The impact of inotersen on neuropathy impairment score in patients with hereditary transthyretin amyloidosis with polyneuropathy","volume":"23","author":"Yarlas","year":"2023","journal-title":"BMC Neurol."},{"key":"10.1016\/j.phrs.2025.107985_bib52","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.amjcard.2020.10.066","article-title":"Impact of tafamidis on Health-Related quality of life in patients with transthyretin amyloid cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial)","volume":"141","author":"Hanna","year":"2021","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.phrs.2025.107985_bib53","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/13506129.2017.1301419","article-title":"Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial","volume":"24","author":"Keohane","year":"2017","journal-title":"Amyloid"},{"key":"10.1016\/j.phrs.2025.107985_bib54","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.amjcard.2021.02.035","article-title":"Causes of cardiovascular hospitalization and death in patients with transthyretin amyloid cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT])","volume":"148","author":"Miller","year":"2021","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.phrs.2025.107985_bib55","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s40256-022-00526-9","article-title":"Annual Cardiovascular-Related hospitalization days avoided with tafamidis in patients with transthyretin amyloid cardiomyopathy","volume":"22","author":"Rozenbaum","year":"2022","journal-title":"Am. J. Cardiovasc Drugs"},{"key":"10.1016\/j.phrs.2025.107985_bib56","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/jamacardio.2023.4147","article-title":"Effect of tafamidis on cardiac function in patients with transthyretin amyloid cardiomyopathy: a post hoc analysis of the ATTR-ACT randomized clinical trial","volume":"9","author":"Shah","year":"2024","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.phrs.2025.107985_bib57","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jaccao.2024.02.007","article-title":"Effect of tafamidis on renal function in patients with transthyretin amyloid cardiomyopathy in ATTR-ACT","volume":"6","author":"Sperry","year":"2024","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.phrs.2025.107985_bib58","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S1474-4422(20)30368-9","article-title":"Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study","volume":"20","author":"Adams","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.phrs.2025.107985_bib59","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1001\/jamaneurol.2024.4631","article-title":"Five-Year results with patisiran for hereditary transthyretin amyloidosis with polyneuropathy: a randomized clinical trial with Open-Label extension","volume":"82","author":"Adams","year":"2025","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.phrs.2025.107985_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2023.2232520","article-title":"Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study","volume":"31","author":"Ticau","year":"2024","journal-title":"Amyloid"},{"key":"10.1016\/j.phrs.2025.107985_bib61","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1111\/ene.14285","article-title":"Early data on long-term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2-year update from the open-label extension of the NEURO-TTR trial","volume":"27","author":"Brannagan","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.phrs.2025.107985_bib62","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1080\/13506129.2017.1357545","article-title":"Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years","volume":"24","author":"Barroso","year":"2017","journal-title":"Amyloid"},{"key":"10.1016\/j.phrs.2025.107985_bib63","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1007\/s00415-013-7051-7","article-title":"Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy","volume":"260","author":"Coelho","year":"2013","journal-title":"J. Neurol."},{"key":"10.1016\/j.phrs.2025.107985_bib64","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.122.009637","article-title":"Long-Term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy","volume":"15","author":"Elliott","year":"2022","journal-title":"Circ. Heart Fail"},{"key":"10.1016\/j.phrs.2025.107985_bib65","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/ejhf.3190","article-title":"Effect of long-term tafamidis treatment on health-related quality of life in patients with transthyretin amyloid cardiomyopathy","volume":"26","author":"Grogan","year":"2024","journal-title":"Eur. J. Heart Fail"},{"key":"10.1016\/j.phrs.2025.107985_bib66","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40120-020-00180-w","article-title":"Evaluation of mortality during Long-Term treatment with tafamidis for transthyretin amyloidosis with polyneuropathy: clinical trial results up to 8.5 years","volume":"9","author":"Merlini","year":"2020","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.phrs.2025.107985_bib67","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.124.072771","article-title":"Long-Term efficacy and safety of acoramidis in ATTR-CM: initial report from the Open-Label extension of the ATTRibute-CM trial","volume":"151","author":"Judge","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2025.107985_bib68","first-page":"25","article-title":"Transthyretin amyloidosis cardiomyopathy in Greece: clinical insights from The National referral center","volume":"79","author":"Bampatsias","year":"2024","journal-title":"Hell. J. Cardiol."},{"key":"10.1016\/j.phrs.2025.107985_bib69","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/ejhf.2028","article-title":"Natural history and impact of treatment with tafamidis on major cardiovascular outcome-free survival time in a cohort of patients with transthyretin amyloidosis","volume":"23","author":"B\u00e9zard","year":"2021","journal-title":"Eur. J. Heart Fail"},{"key":"10.1016\/j.phrs.2025.107985_bib70","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00392-022-02035-w","article-title":"Therapeutic value of tafamidis in patients with wild-type transthyretin amyloidosis (ATTRwt) with cardiomyopathy based on cardiovascular magnetic resonance (CMR) imaging","volume":"112","author":"Chamling","year":"2023","journal-title":"Clin. Res Cardiol."},{"key":"10.1016\/j.phrs.2025.107985_bib71","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.cardfail.2024.06.003","article-title":"Survival in a Real-World cohort of patients with transthyretin amyloid cardiomyopathy treated with tafamidis: an analysis from the transthyretin amyloidosis outcomes survey (THAOS)","volume":"31","author":"Garcia-Pavia","year":"2025","journal-title":"J. Card. Fail"},{"key":"10.1016\/j.phrs.2025.107985_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2023.101667","article-title":"Real-World efficacy of tafamidis in patients with transthyretin amyloidosis and heart failure","volume":"48","author":"Ghoneem","year":"2023","journal-title":"Curr. Probl. Cardiol."},{"key":"10.1016\/j.phrs.2025.107985_bib73","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/ehjci\/jeac049","article-title":"Effect of tafamidis on global longitudinal strain and myocardial work in transthyretin cardiac amyloidosis","volume":"23","author":"Giblin","year":"2022","journal-title":"Eur. Heart J. Cardiovasc Imaging"},{"key":"10.1016\/j.phrs.2025.107985_bib74","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jaccao.2022.07.007","article-title":"Prognosis of transthyretin cardiac amyloidosis without heart failure symptoms","volume":"4","author":"Gonzalez-Lopez","year":"2022","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.phrs.2025.107985_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2022.101358","article-title":"Impact of tafamidis on survival in a Real-World Community-Based cohort","volume":"47","author":"Hussain","year":"2022","journal-title":"Curr. Probl. Cardiol."},{"key":"10.1016\/j.phrs.2025.107985_bib76","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.cardfail.2019.11.024","article-title":"Stabilization of cardiac function with diflunisal in transthyretin (ATTR) cardiac amyloidosis","volume":"26","author":"Lohrmann","year":"2020","journal-title":"J. Card. Fail"},{"key":"10.1016\/j.phrs.2025.107985_bib77","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40120-018-0097-9","article-title":"Positive effectiveness of tafamidis in delaying disease progression in transthyretin familial amyloid polyneuropathy up to 2 years: an analysis from the transthyretin amyloidosis outcomes survey (THAOS)","volume":"7","author":"Mundayat","year":"2018","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.phrs.2025.107985_bib78","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1253\/circj.CJ-21-0965","article-title":"Early experience of tafamidis treatment in Japanese patients with Wild-Type transthyretin cardiac amyloidosis from the kochi amyloidosis cohort","volume":"86","author":"Ochi","year":"2022","journal-title":"Circ. J."},{"key":"10.1016\/j.phrs.2025.107985_bib79","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004769","article-title":"TTR (Transthyretin) stabilizers are associated with improved survival in patients with TTR cardiac amyloidosis","volume":"11","author":"Rosenblum","year":"2018","journal-title":"Circ. Heart Fail"},{"key":"10.1016\/j.phrs.2025.107985_bib80","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/13506129.2021.2000388","article-title":"Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy: the Boston university amyloidosis center experience","volume":"29","author":"Siddiqi","year":"2022","journal-title":"Amyloid"},{"key":"10.1016\/j.phrs.2025.107985_bib81","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1002\/ehf2.14380","article-title":"Clinical characteristics, outcome, and therapeutic effect of tafamidis in wild-type transthyretin amyloid cardiomyopathy","volume":"10","author":"Takashio","year":"2023","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.phrs.2025.107985_bib82","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13023-024-03198-7","article-title":"Treatment characteristics of patients with hereditary transthyretin amyloidosis: a cohort study","volume":"19","author":"Qarni","year":"2024","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.phrs.2025.107985_bib83","doi-asserted-by":"crossref","first-page":"59","DOI":"10.5334\/gh.1262","article-title":"World heart federation consensus on transthyretin amyloidosis cardiomyopathy (ATTR-CM)","volume":"18","author":"Brito","year":"2023","journal-title":"Glob. Heart"},{"key":"10.1016\/j.phrs.2025.107985_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106805","article-title":"Efficacy, safety, quality of life, adherence and cost-effectiveness of long-acting growth hormone replacement therapy compared to daily growth hormone in children with growth hormone deficiency: a systematic review and meta-analysis","volume":"193","author":"Mameli","year":"2023","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2025.107985_bib85","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1007\/s11136-019-02214-9","article-title":"A systematic review of quality of life research in Medicine and health sciences","volume":"28","author":"Haraldstad","year":"2019","journal-title":"Qual. Life Res"},{"key":"10.1016\/j.phrs.2025.107985_bib86","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.amjcard.2022.05.003","article-title":"Relation of body mass index to transthyretin cardiac amyloidosis particularly in black and hispanic patients (from the SCAN-MP Study)","volume":"177","author":"Poterucha","year":"2022","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.phrs.2025.107985_bib87","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3390\/cardiogenetics12020017","article-title":"Modified body mass index as a novel nutritional and prognostic marker in patients with cardiac amyloidosis","volume":"12","author":"Dongiglio","year":"2022","journal-title":"Cardiogenetics"},{"key":"10.1016\/j.phrs.2025.107985_bib88","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/13506129.2019.1698417","article-title":"Markers of nutritional status and inflammation in transthyretin cardiac amyloidosis: association with outcomes and the clinical phenotype","volume":"27","author":"Driggin","year":"2020","journal-title":"Amyloid"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825004104?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825004104?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T04:29:12Z","timestamp":1762489752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661825004104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":88,"alternative-id":["S1043661825004104"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2025.107985","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drugs for transthyretin amyloidosis under the microscope: Survival, safety, and a meta-analysis with certainty of evidence assessment","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2025.107985","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107985"}}